Janus Henderson Group PLC's Form 4 filing
Oruka Therapeutics, Inc. (ORKA) · filed Jul 26, 2024
- Accession no.
- 0001437749-24-023533
- Filed
- Jul 26, 2024, 10:50 AM ET
- Trade date
- Jul 24-25, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $699.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Janus Henderson Group PLCCIK 0001274173 | 10% Owner |
| Janus Henderson Biotech Innovation Master Fund LtdCIK 0002030299 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 24, 2024 | Common Stock | PPurchaseAcquired | +165,000 | $3.20 | +$528,000 | 2,056,312 | Indirect | |
| Jul 24, 2024 | Common Stock | PPurchaseAcquired | +17,800 | $3.18 | +$56,595.1 | 2,074,112 | Indirect | |
| Jul 24, 2024 | Common Stock | PPurchaseAcquired | +7,056 | $3.16 | +$22,277.91 | 2,081,168 | Indirect | |
| Jul 25, 2024 | Common Stock | PPurchaseAcquired | +30,227 | $3.05 | +$92,292.1 | 2,111,395 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.